HOME >> BIOLOGY >> NEWS
Turning down the Sun

reduction in fossil fuels might entail.

"Teller and Wood are technical optimists, and pessimists about human behaviour," says Caldeira, who saw Wood present their work in 1998, and was disturbed by the re-emergence of these Sun-blocking proposals. "My hope was to show that it wouldn't work," he says, "so people would give up on it."

Caldeira thought he saw a central flaw in all of these Sun-dimming ideas. While reducing sunlight might have an overall cooling effect on the planet as a whole, he argued, it wouldn't counteract the local heating effect from CO2. The two forces act in a completely different way on different parts of the globe. The capacity of CO2 to trap heat increases with temperature, so it's more effective near the equator. The Sun, on the other hand, shines more in the northern hemisphere in June, more in the southern hemisphere in December. Surely, thought Caldeira, these very different phenomena couldn't exactly cancel each other out? Not on a country-sized scale, or over the different seasons. Instead, he expected the winters to get warmer and the summers cooler, the poles warmer and the tropics cooler. In short, many of the problems the Earth faces from global warming-the seasons becoming more and more alike, and a variety of weird weather (New Scientist, 16 September, p 26)-would be made worse.

To try to prove his hypothesis, Caldeira went to work with his colleague Bala Govindasamy and a hefty climate-modelling program. They invented three future worlds to test. In the first, the control model, levels of atmospheric CO2 were set at just 280 parts per million-the pre-industrial value-and the Sun shone at a constant 1367 watts per square metre at the Earth's surface. In the second, there was twice as much CO2, adding an extra 4.17 watts per square metre to the Earth-bound radiation. In the final, geoengineered scenario, the doubled CO2 was countered by cutting 1.8 per cent of the Sun's light, again worth 4.17 watts per square metre.
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
19-Sep-2000


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Turning bone into nerve
2. Turning foe into friend with lentiviral vectors
3. Turning off building lights reduces bird window-kill by 83%
4. Turning blood into brain: new studies suggest bone marrow stem cells can develop into neurons in living animals
5. Turning salt and water into wine
6. UNC Researchers Reduce Arthritis Severity By Turning Off Molecular Switch
7. Turning "Unrecyclable" Waste Into Plastic Products
8. Survey Shows Students Turning To Physicians Less As Drug Abuse Increases
9. Africa At The Turning Point
10. Nitric Oxide Found To Control Cells By Turning On Genes; Suggests New Role In Health And Disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Turning down the Sun

(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: